vs
Side-by-side financial comparison of Ascent Solar Technologies, Inc. (ASTI) and Silo Pharma, Inc. (SILO). Click either name above to swap in a different company.
Silo Pharma, Inc. is the larger business by last-quarter revenue ($18.0K vs $15.6K, roughly 1.2× Ascent Solar Technologies, Inc.). Over the past eight quarters, Ascent Solar Technologies, Inc.'s revenue compounded faster (67.1% CAGR vs 0.0%).
Ascent Solar Technologies, Inc. is a publicly traded photovoltaic (PV) company located in Thornton, Colorado. Its primary product is a flexible CIGS solar cell on a plastic substrate.
The Pharma Documentation Ring (P-D-R), founded in 1958, is a think tank of information and knowledge-management professionals representing major research-based pharmaceutical companies. The association has four aims:Promote exchange of knowledge among members Encourage commercial development of new information services and systems Jointly assess new and existing products and services Provide a forum for the information industry
ASTI vs SILO — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.6K | $18.0K |
| Net Profit | — | $-1.1M |
| Gross Margin | — | -14.8% |
| Operating Margin | — | -6388.2% |
| Net Margin | — | -6160.5% |
| Revenue YoY | — | 0.0% |
| Net Profit YoY | -42.3% | -19.6% |
| EPS (diluted) | — | $-0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.6K | — | ||
| Q3 25 | $28.5K | $18.0K | ||
| Q2 25 | $17.0K | $18.0K | ||
| Q1 25 | $15.6K | $18.0K | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $8.6K | $18.0K | ||
| Q2 24 | $27.7K | $18.0K | ||
| Q1 24 | $5.6K | $18.0K |
| Q4 25 | — | — | ||
| Q3 25 | $-2.0M | $-1.1M | ||
| Q2 25 | $-2.1M | $-1.2M | ||
| Q1 25 | $-1.7M | $-1.0M | ||
| Q4 24 | $-1.5M | — | ||
| Q3 24 | $-1.7M | $-928.8K | ||
| Q2 24 | $-3.4M | $-931.8K | ||
| Q1 24 | $-2.5M | $-801.7K |
| Q4 25 | — | — | ||
| Q3 25 | — | -14.8% | ||
| Q2 25 | — | 91.9% | ||
| Q1 25 | — | 91.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 91.9% | ||
| Q2 24 | — | 91.9% | ||
| Q1 24 | — | 91.9% |
| Q4 25 | — | — | ||
| Q3 25 | -6892.3% | -6388.2% | ||
| Q2 25 | -12316.8% | -6926.8% | ||
| Q1 25 | -11177.9% | -6069.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -26443.2% | -5603.6% | ||
| Q2 24 | -8490.7% | -5563.2% | ||
| Q1 24 | -44206.0% | -4879.1% |
| Q4 25 | — | — | ||
| Q3 25 | -7081.3% | -6160.5% | ||
| Q2 25 | -12177.3% | -6681.2% | ||
| Q1 25 | -10716.2% | -5721.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | -19776.2% | -5152.9% | ||
| Q2 24 | -12420.5% | -5169.4% | ||
| Q1 24 | -45316.8% | -4447.3% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.62 | $-0.12 | ||
| Q2 25 | $-1.17 | $-0.19 | ||
| Q1 25 | $-1.13 | $-0.23 | ||
| Q4 24 | $50.75 | — | ||
| Q3 24 | $-1.37 | $-0.22 | ||
| Q2 24 | $-6.76 | $-0.31 | ||
| Q1 24 | $-53.00 | $-0.28 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.8M | $5.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.3M | $5.0M |
| Total Assets | $6.3M | $6.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.8M | — | ||
| Q3 25 | $2.1M | $5.9M | ||
| Q2 25 | $3.0M | $6.3M | ||
| Q1 25 | $2.3M | $5.5M | ||
| Q4 24 | $3.2M | — | ||
| Q3 24 | $3.7M | $8.0M | ||
| Q2 24 | $5.8M | $7.6M | ||
| Q1 24 | $187.5K | $6.7M |
| Q4 25 | $3.3M | — | ||
| Q3 25 | $2.7M | $5.0M | ||
| Q2 25 | $3.4M | $4.9M | ||
| Q1 25 | $2.6M | $4.0M | ||
| Q4 24 | $3.4M | — | ||
| Q3 24 | $-3.3M | $6.8M | ||
| Q2 24 | $4.2M | $6.0M | ||
| Q1 24 | $-2.6M | $5.3M |
| Q4 25 | $6.3M | — | ||
| Q3 25 | $5.8M | $6.4M | ||
| Q2 25 | $6.8M | $6.7M | ||
| Q1 25 | $6.2M | $5.9M | ||
| Q4 24 | $7.1M | — | ||
| Q3 24 | $7.9M | $8.6M | ||
| Q2 24 | $10.2M | $8.0M | ||
| Q1 24 | $5.0M | $6.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.9M | $-955.5K |
| Free Cash FlowOCF − Capex | $-6.9M | — |
| FCF MarginFCF / Revenue | -44350.5% | — |
| Capex IntensityCapex / Revenue | 204.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-12.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.9M | — | ||
| Q3 25 | $-1.7M | $-955.5K | ||
| Q2 25 | $-1.8M | $-1.3M | ||
| Q1 25 | $-1.6M | $-1.6M | ||
| Q4 24 | $-1.5M | — | ||
| Q3 24 | $-2.1M | $-1.3M | ||
| Q2 24 | $-3.6M | $-731.8K | ||
| Q1 24 | $-1.2M | $-838.2K |
| Q4 25 | $-6.9M | — | ||
| Q3 25 | $-1.8M | — | ||
| Q2 25 | $-1.8M | — | ||
| Q1 25 | $-1.6M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -44350.5% | — | ||
| Q3 25 | -6182.5% | — | ||
| Q2 25 | -10692.4% | — | ||
| Q1 25 | -9923.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 204.7% | — | ||
| Q3 25 | 103.3% | — | ||
| Q2 25 | 12.0% | — | ||
| Q1 25 | 3.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
